{"id":450,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-development-status-2026-evidence-map","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/retatrutide-development-status-2026-evidence-map\/","title":{"rendered":"\u00c9tat de d\u00e9veloppement de Retatrutide dans 2026\u00a0: une carte de donn\u00e9es probantes pour les chercheurs"},"content":{"rendered":"

Les compos\u00e9s en phase de d\u00e9veloppement cr\u00e9ent un probl\u00e8me r\u00e9current de pr\u00e9cision du r\u00e9f\u00e9rencement\u00a0: les annonces d'essais, l'\u00e9tat des registres, les rapports de conf\u00e9rence, les articles de revues et les approbations sont souvent m\u00e9lang\u00e9s dans un seul calendrier. Cette carte de preuves s\u00e9pare ces jalons pour la retatrutide.<\/p>

Points cl\u00e9s \u00e0 retenir<\/h2>
  • Les r\u00e9sultats de la phase 2 \u00e9valu\u00e9s par les pairs et un enregistrement du registre 3 de la phase termin\u00e9e sont des objets de preuve diff\u00e9rents.<\/li>
  • ClinicalTrials.gov n'affiche toujours aucun r\u00e9sultat publi\u00e9 pour TRIUMPH-1, alors que les principales divulgations du sponsor 2026 existent d\u00e9sormais\u00a0; ces objets de preuve sont rapport\u00e9s s\u00e9par\u00e9ment ci-dessous.<\/li>
  • Le statut r\u00e9glementaire doit \u00eatre v\u00e9rifi\u00e9 par rapport aux enregistrements FDA, et non d\u00e9duit de la couverture m\u00e9diatique ou de la disponibilit\u00e9 du catalogue.<\/li><\/ul><\/div><\/div>
    \"Chercheur
    Illustration conceptuelle de la recherche multi-r\u00e9cepteurs\u00a0; aucun r\u00e9sultat d'essai ou pr\u00e9sentation du produit n'est repr\u00e9sent\u00e9.<\/figcaption><\/figure>

    L'\u00e9chelle des preuves<\/h2>

    Un registre d'essai r\u00e9pond aux questions de protocole et de statut\u00a0: ce qui \u00e9tait pr\u00e9vu, qui \u00e9tait \u00e9ligible, quels r\u00e9sultats ont \u00e9t\u00e9 d\u00e9sign\u00e9s et si le recrutement ou le suivi est termin\u00e9. Un article de revue r\u00e9pond \u00e0 un ensemble diff\u00e9rent de questions apr\u00e8s analyse des donn\u00e9es et examen par les pairs. Un dossier d'approbation FDA ajoute une d\u00e9termination r\u00e9glementaire ind\u00e9pendante pour un produit sp\u00e9cifique.<\/p>

    Publi\u00e9<\/strong>Essai de phase 2 sur l'ob\u00e9sit\u00e9 avec des r\u00e9sultats \u00e9valu\u00e9s par des pairs<\/span><\/div>
    Inscrit\/compl\u00e9t\u00e9<\/strong>Enregistrement 3 de la phase TRIUMPH-1\u00a0; informations sur l'\u00e9tat et le protocole<\/span><\/div>
    Commanditaire signal\u00e9<\/strong>R\u00e9sultats de la premi\u00e8re phase 2026 3\u00a0; rapports pas encore complets \u00e9valu\u00e9s par des pairs<\/span><\/div>
    ClinicalTrials.gov<\/strong>TRIUMPH-1 affiche toujours Aucun r\u00e9sultat publi\u00e9<\/span><\/div>
    Non \u00e9tabli<\/strong>Approbation FDA pour le r\u00e9tatrutide<\/span><\/div><\/div><\/div>

    Comment mettre \u00e0 jour cette page de mani\u00e8re responsable<\/h2>

    Lorsqu'un registre change, enregistrez la date de mise \u00e0 jour et d\u00e9crivez uniquement le champ modifi\u00e9. Lorsque les r\u00e9sultats apparaissent, associez l'enregistrement des r\u00e9sultats ou la publication \u00e9valu\u00e9e par des pairs et distinguez les param\u00e8tres pr\u00e9d\u00e9finis des analyses exploratoires. Lorsque le statut r\u00e9glementaire change, remplacez l'ancienne d\u00e9claration de statut (et ne vous contentez pas de l'ajouter en annexe).<\/p>

    N'actualisez pas la date de l'article sans modifications substantielles des preuves. Les conseils de Google ax\u00e9s sur les personnes mettent explicitement en garde contre la modification des dates uniquement pour donner l\u2019impression que le contenu est nouveau.<\/p>

    Phase sup\u00e9rieure de 3 rapport\u00e9e par le sponsor 2026<\/h2>

    Lilly a rapport\u00e9 les premiers r\u00e9sultats pour TRIUMPH-1 en mai 21, 2026\u00a0: au cours des semaines 80, le sponsor a signal\u00e9 un changement de poids moyen de \u221228.3% pour le groupe 12 mg. En juillet 23, 2026, Lilly a signal\u00e9 des changements moyens allant jusqu'\u00e0 \u221220.8% dans TRIUMPH-2 et \u221222.6% dans TRIUMPH-3. Il s\u2019agit de divulgations du sponsor principal, et non de modules de r\u00e9sultats de ClinicalTrials.gov ou de rapports complets \u00e9valu\u00e9s par des pairs\u00a0; les m\u00e9thodes d\u00e9taill\u00e9es, les d\u00e9cisions d\u2019analyse et les tableaux complets des \u00e9v\u00e9nements ind\u00e9sirables n\u00e9cessitent toujours les \u00e9ventuels enregistrements complets. ClinicalTrials.gov a continu\u00e9 \u00e0 afficher \u00ab\u00a0Aucun r\u00e9sultat publi\u00e9\u00a0\u00bb pour TRIUMPH-1 lors de cette revue.<\/p>

    Implications pour les pages de recherche de catalogue<\/h2>

    Une page de catalogue peut utiliser le calendrier de d\u00e9veloppement pour orienter les chercheurs, mais doit maintenir une s\u00e9paration entre les preuves documentaires et la qualit\u00e9 des lots. Il doit \u00eatre li\u00e9 aux modules de sp\u00e9cifications et de preuves de la famille et doit indiquer que le mat\u00e9riel n\u2019est pas destin\u00e9 \u00e0 un usage humain ou v\u00e9t\u00e9rinaire.<\/p>","protected":false},"excerpt":{"rendered":"

    Une carte de preuves 2026 s\u00e9parant les donn\u00e9es publi\u00e9es de la phase 2 du r\u00e9tatrutide, les enregistrements de l'\u00e9tude de la phase 3 termin\u00e9e, les r\u00e9sultats non publi\u00e9s et le statut r\u00e9glementaire.<\/p>","protected":false},"author":1,"featured_media":620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Development-status evidence map","pim_evidence_level":"Trial registry, peer-reviewed phase 2 evidence and FDA status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Retatrutide phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Peer-reviewed outcomes.\"},{\"title\":\"TRIUMPH-1 ClinicalTrials.gov record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"Protocol and current study-status record.\"},{\"title\":\"FDA current information on retatrutide status\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Authoritative regulatory boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"},{\"title\":\"Google guidance on people-first content and substantive date changes\",\"url\":\"https:\/\/developers.google.com\/search\/docs\/fundamentals\/creating-helpful-content\",\"note\":\"Official Google Search Central guidance cited for the editorial-update statement.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nRetatrutide Development Status in 2026: An Evidence Map for Researchers - NHD<\/title>\n<meta name=\"description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/retatrutide-development-status-2026-evidence-map\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\" \/>\n<meta property=\"og:description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/retatrutide-development-status-2026-evidence-map\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u00c9tat de d\u00e9veloppement de Retatrutide dans 2026\u00a0: une carte de donn\u00e9es probantes pour les chercheurs - NHD","description":"Une carte de preuves 2026 s\u00e9parant les donn\u00e9es publi\u00e9es de la phase 2 du r\u00e9tatrutide, les enregistrements de l'\u00e9tude de la phase 3 termin\u00e9e, les r\u00e9sultats non publi\u00e9s et le statut r\u00e9glementaire.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/retatrutide-development-status-2026-evidence-map\/","og_locale":"fr_FR","og_type":"article","og_title":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","og_description":"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.","og_url":"https:\/\/nhdbio.com\/fr\/retatrutide-development-status-2026-evidence-map\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","url":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","name":"\u00c9tat de d\u00e9veloppement de Retatrutide dans 2026\u00a0: une carte de donn\u00e9es probantes pour les chercheurs - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Une carte de preuves 2026 s\u00e9parant les donn\u00e9es publi\u00e9es de la phase 2 du r\u00e9tatrutide, les enregistrements de l'\u00e9tude de la phase 3 termin\u00e9e, les r\u00e9sultats non publi\u00e9s et le statut r\u00e9glementaire.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Development Status in 2026: An Evidence Map for Researchers"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=450"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/450\/revisions"}],"predecessor-version":[{"id":530,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/450\/revisions\/530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/620"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}